Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$8.03
-0.8%
$8.52
$6.51
$13.27
$8.51M1.631,088 shs492 shs
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.05
$0.07
$0.02
$0.78
$2.26M1.174,709 shs32 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$2.06
+18.4%
$1.08
$0.47
$5.24
$10.53M1.32448,341 shs289,547 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$5.08
+0.3%
$3.42
$1.75
$6.92
$8.34M1.251.55 million shs143,673 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
-2.97%-0.37%-1.67%-3.26%+5.33%
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%-1.12%+59.16%+51.86%+158.54%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%+5.45%+83.12%+114.29%+837.00%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.59%-3.98%+42.13%+57.63%+2,178.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
2.3465 of 5 stars
3.53.00.00.00.00.80.6
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
1.3707 of 5 stars
0.05.00.00.03.30.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
3.00
Buy$30.00273.83% Upside
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$460K18.49N/AN/A$10.37 per share0.77
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M0.70N/AN/A($2.06) per share-0.03
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.91M0.55N/AN/A$2.47 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$8.02M-$0.34N/AN/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.89N/AN/AN/A-123.06%-94.28%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.46N/AN/AN/A-23.87%-50.00%-16.79%11/6/2025 (Estimated)

Latest ADXS, MTNB, SNOA, and ADXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q1 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.51-$0.37+$0.14-$0.76$4.26 million$4.01 million
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/A
3.02
3.02
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.70
1.92

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
16.14%
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
15.00%
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
24.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
301.06 million901,000Not Optionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.24 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$8.02 -0.07 (-0.80%)
As of 03:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.05 0.00 (0.00%)
As of 08/21/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$2.06 +0.32 (+18.39%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$5.08 +0.02 (+0.30%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.